natgillin/translations-raw huggingface dataset:
The solution should be administered immediately after preparation. 
To raztopino je treba dati takoj, ko je pripravljena.
Skin and subcutaneou s tissue disorders rash angioede ma, urticaria 
Bolezni kože in podkožja izpuščaj angioede m, urtikarija
Body weight (kg) 
Telesna masa (v kg)
Based on the available data the first oscillatory potential and 30 Hz flicker responses of the electroretinogram appear to be correlated with a vigabatrin associated VFD. 
Zdi se, da sta prvi oscilatorni potencial in odzivi 30 Hz bliskovnega elektroretinograma po razpoložljivih podatkih v tesni zvezi z izpadom vidnega polja, povezanega z vigabatrinom.
New onset myoclonus and exacerbation of existing myoclonus may occur in rare cases. 
V redkih primerih lahko pride do novih nastopov mioklonusa in poslabšanja obstoječega mioklonusa.
Investigation s weight increased 
Preiskave povečana telesna masa
For patients who cannot swallow, administration of Kigabeq using a gastric tube is possible. 
Bolnikom, ki ne morejo požirati, je zdravilo Kigabeq mogoče dati z gastrično sondo.
The doctor will check your child's visual field before your child starts taking vigabatrin and carry on checking it at regular intervals during the treatment. 
Preden bo vaš otrok začel jemati vigabatrin, bo zdravnik preveril njegovo vidno polje in ga bo med zdravljenjem redno preverjal.
Vigabatrin should not be used concomitantly with other retinotoxic medicinal products. 
Vigabatrin se ne sme uporabljati sočasno z drugimi zdravili, ki so toksična za mrežnico.
Decreases in ALT and AST, which are considered to be a result of inhibition of these aminotransferases by vigabatrin, have been observed. 
Opazili so zmanjšanja ALT in AST, za katere velja, da je do njih prišlo, ker vigabatrin zavira te aminotransferaze.
Other medicines and Kigabeq 
Druga zdravila in zdravilo Kigabeq
• Rinse the glass or beaker with one or two teaspoonfuls (about 5 to 10 ml) of water and give this to your child to make sure that the child receives all the medicine 
• Splaknite kozarec ali čašo z eno ali dvema čajnima žličkama (približno od 5 do 10 ml) in to mešanico dajte svojemu otroku, da bo zagotovo prejel celotno zdravilo.
Other less frequently reported symptoms included vertigo, headache, psychosis, respiratory depression or apnoea, bradycardia, hypotension, agitation, irritability, confusion, abnormal behaviour, and speech disorder. 
Drugi simptomi, o katerih so poročali manj pogosto, so vključevali vrtoglavico, glavobol, psihozo, respiratorno depresijo ali apnejo, bradikardijo, hipotenzijo, vznemirjenje, razdražljivost, zmedenost, neobičajno vedenje in motnje govora.
Patients with myoclonic seizures may be particularly susceptible to this effect. 
Za ta učinek so lahko še posebej dojemljivi bolniki z miokloničnimi napadi.
Some patients may experience an increase in seizure frequency, including status epilepticus with vigabatrin. 
Pri nekaterih bolnikih se lahko zaradi vigabatrina pogostnost napadov, vključno z epileptičnim statusom, poveča.
The tube should be rinsed with 10 ml of water 
Sondo je treba splakniti z 10 ml vode.
If your child has visual disturbances, contact your child's doctor or hospital immediately. 
Če ima vaš otrok motnje vida, se takoj posvetujte z njegovim zdravnikom ali bolnišnico.
Since vigabatrin is eliminated via the kidneys, caution should be exercised when administering the medicinal product to patients with creatinine clearance less than 60 ml/min. 
Ker se vigabatrin izloča prek ledvic, je pri dajanju zdravila bolnikom, pri katerih je očistek kreatinina manjši od 60 ml/min, potrebna previdnost.
What Kigabeq is and what it is used for 
Kaj je zdravilo Kigabeq in za kaj ga uporabljamo
A deterioration of VFD after the treatment is discontinued cannot be excluded. 
Poslabšanja izpadov vidnega polja po prekinitvi zdravljenja ni mogoče izključiti.
Electroretinography is recommended in infants and children who are unable to cooperate with perimetry. 
Pri dojenčkih in otrocih, ki pri perimetriji ne morejo sodelovati, se priporoča elektroretinografija.
No teratogenicity was seen in rats in doses up to 150 mg/kg (3 times the human dose) or in rabbits in doses up to 100 mg/kg. 
Pri podganah, ki so prejemale odmerke do 150 mg/kg (kar je 3-kratna vrednost odmerka pri človeku) in pri kuncih, ki so prejemali odmerke do 100 mg/kg, niso opazili teratogenosti.
Movement disorders can occur in young infants treated for infantile spasms (West's syndrome). 
Pri majhnih dojenčkih, zdravljenih zaradi infantilnih spazmov (Westovega sindroma) se lahko pojavijo motnje gibanja.
If your child has these symptoms, you should tell his/her doctor immediately hives or nettle rash marked sedation (sleepiness), stupor and confusion (encephalopathy). 
Če so se pri vašem otroku pojavili ti simptomi, morate to takoj povedati njegovemu zdravniku; koprivnica ali urtikarija; izražena sedacija (zaspanost), omamljenost in zmedenost (encefalopatija).
If your child takes too much Kigabeq 
Če otrok vzame preveč zdravila Kigabeq
Available data suggests that visual field defects are irreversible. 
Razpoložljivi podatki kažejo, da so izpadi vidnega polja ireverzibilni.
This medicinal product is not intended for use in women who are breastfeeding. 
To zdravilo ni namenjeno uporabi pri ženskah, ki dojijo.
The most commonly reported adverse reaction related to vigabatrin are visual field defects (ranging from mild to severe and occurring usually after months to years of vigabatrin therapy), psychiatric disorders such as agitation, excitation, aggression, nervousness, depression, paranoid reaction, nervous system disorders such as marked sedation, stupor and confusion. 
Neželeni učinki, povezani z vigabatrinom, o katerih so največkrat poročali, so izpadi vidnega polja (ki segajo od blagih do resnih in se običajno pojavljajo nekaj mesecev ali let po zdravljenju z vigabatrinom), psihične motnje, kot so vznemirjenje, razburjenje, agresija, živčnost, depresija, paranoidna reakcija, ter motnje živčnega sistema, kot so izražena sedacija, omamljenost in zmedenost.
If you have any further questions, ask your child's doctor or pharmacist. 
- Če imate dodatna vprašanja, se posvetujte z otrokovim zdravnikom ali farmacevtom.
• Pour one or two teaspoonfuls (about 5 to 10 ml) of water into a drinking glass or beaker 
• Eno ali dve čajni žlici (približno od 5 do 10 ml) vode nalijte v kozarec ali čašo.
Table 2: Number of soluble tablets according to body weight and starting dose in resistant partial epilepsy 
Preglednica 2: število tablet za peroralno raztopino v skladu s telesno maso in začetnim odmerkom pri rezistentni delni epilepsiji Telesna masa (kg)
If at any time your child has had these symptoms, immediately contact child's doctor. 
Če so bili pri vašem otroku kadar koli izraženi taki simptomi, se takoj posvetujte z njegovim zdravnikom.
Always check the label and the size of the tablets to make sure you are giving the right dose. 
Da boste zagotovo dali pravi odmerek, vedno preverite nalepko in velikost tablet.
Vigabatrin treatment may only be initiated by a specialist in epileptology, neurology or paediatric neurology. 
Zdravljenje z vigabatrinom lahko uvede le specialist na področju epileptologije, nevrologije ali pediatrične nevrologije.
These side effects usually stop when doses are reduced or the medicine is gradually discontinued. 
Ti neželeni učinki običajno izginejo ob zmanjšanju odmerkov ali ob postopni ukinitvi zdravila.
The method of administration will be determined by a physician specialised in epileptology, neurology or paediatric neurology. 
Način uporabe bo določil zdravnik, specializiran za epileptologijo, nevrologijo ali pediatrično nevrologijo.
This visual field defect can range from mild to severe. 
Ta okvara vidnega polja je lahko blaga do resna.
Visual field defects (VFD) have been reported in patients receiving vigabatrin with a high prevalence (about 1/3 of patients). 
Pri bolnikih, ki so prejemali vigabatrin, so poročali o visoki prevalenci izpadov vidnega polja (pojavili so se pri 1/3 bolnikov).
These reactions occurred in patients with and without a psychiatric history and were usually reversible when vigabatrin doses were reduced or gradually discontinued (see section 4.4). 
Do teh reakcij je prišlo pri bolnikih s psihiatrično anamnezo in pri bolnikih brez nje, običajno pa so bili ob zmanjšanju odmerkov vigabatrina ali postopni prekinitvi zdravljenja z njim reverzibilni (glejte poglavje 4.4).
Some patients may experience an increase in seizure frequency or the onset of new types of seizures with vigabatrin (see section 4.8). 
Pri nekaterih bolnikih se lahko zaradi vigabatrina poveča pogostnost napadov ali pa pride do nastopa novih vrst napadov (glejte poglavje 4.8).
Activated charcoal has been shown to not significantly adsorb vigabatrin in an in vitro study. 
V študiji in vitro je bilo dokazano, da aktivirano oglje vigabatrina ne adsorbira v pomembni meri.
These events occurred in patients with and without a psychiatric history and were usually reversible when vigabatrin doses were reduced or gradually discontinued. 
Do teh dogodkov je prišlo pri bolnikih s psihiatrično anamnezo in pri bolnikih brez nje, običajno pa so bili ob zmanjšanju odmerkov vigabatrina ali postopni ukinitvi zdravljenja z njim reverzibilni.
Nervous system disorders somnolenc e speech disorder, headache, dizziness, paraesthesia, disturbance in attention and memory impairment, mental impairment (thought disturbance), tremor coordination abnormal (ataxia) 
Bolezni živčevja zaspanost motnja govora, glavobol, omotica, parestezija, motnja pozornosti in poslabšanje spomina, duševne motnje (motnja razmišljanja), drget neobičajna koordinacija (ataksija)
Psychiatric reactions have been reported during vigabatrin therapy. 
Med zdravljenjem z vigabatrinom so poročali o psihiatričnih reakcijah.
Eye disorders visual field defect vision blurred, diplopia, nystagmus retinal disorder (such as peripheral retinal atrophy) 
Očesne bolezni izpad vidnega polja zamegljen vid, diplopija, nistagmus bolezen mrežnice (kot je atrofija periferne mrežnice)
Follow-up should be arranged under supervision of a specialist in epileptology, neurology or paediatric neurology. 
Organizirati je treba kontrolne preglede pod nadzorom specialista na področju epileptologije, nevrologije ali pediatrične nevrologije.
Patients should undergo systematic screening examination when starting vigabatrin and at regular intervals for detection of visual field defects. 
Za odkrivanje izpadov vidnega polja morajo bolniki ob začetku jemanja vigabatrina in v rednih časovnih presledkih opraviti sistematski presejalni pregled.
The mean Cl/F of active S-enantiomer of vigabatrin in infants and children was 0.591 l/h/kg and 0.446 l/h/kg respectively. 
0,591 l/uro/kg oziroma 0,446 l/uro/kg.
How to give Kigabeq 
Kako dajati zdravilo Kigabeq
Kigabeq contains vigabatrin and it is used for treating infants and children aged from 1 month to less than 7 years. 
Zdravilo Kigabeq vsebuje vigabatrin in se uporablja za zdravljenje dojenčkov in otrok, starih od
If you forget to give your child Kigabeq 
Če ste otroku pozabili dati zdravilo Kigabeq
Contact the doctor if your child has these effects suicide attempt other eye problems such as retinal disorder, causing, for example, poor vision at night and difficulty adjusting from bright to dim areas, sudden or unexplained loss of vision, sensitivity to light 
druge težave z očmi, kot je bolezen mrežnice, ki na primer povzroča slab nočni vid in težave pri prilagajanju na prehod iz svetlih na zatemnjena območja, nenadna ali nepojasnjena izguba vida, občutljivost na svetlobo.
Common Uncommon Rare Very rare Not known 
Neznana pogostnost
You must speak to your child's doctor if your child's condition does not improve within a month of starting vigabatrin. 
Če se stanje vašega otroka v enem mesecu po začetku zdravljenja z vigabatrinom ne spremeni, morate govoriti z njegovim zdravnikom.
Ös te rreich 
Okvara ledvic
Visual field defects 
Izpadi vidnega polja
Dose (mg per day) 
Odmerek (mg na dan)
Musculoskel etal and connective tissue disorders arthralgia 
Bolezni mišičnoskeletnega sistema in vezivnega artralgija tkiva
Table 1: Number of soluble tablets according to body weight, starting dose and dose increment in infantile spasms Body we ight (kg) 
Preglednica 1: število tablet za peroralno raztopino glede na telesno maso, začetni odmerek in povečanje odmerka pri infantilnih spazmih
The clinical significance of these MRI abnormalities is unknown. 
Klinična pomembnost teh nepravilnosti pri slikanju z magnetno resonanco ni znana.
Such reactions have been fully reversible following dose reduction or discontinuation of vigabatrin (see section 4.4). 
Takšne reakcije so bile po zmanjšanju odmerka ali prekinitvi zdravljenja z vigabatrinom popolnoma reverzibilne (glejte poglavje 4.4).
• The mixture will be whitish and cloudy. 
• Mešanica bo belkasta in motna.
However, the VFDs reported in patients receiving vigabatrin have ranged from mild to severe. 
Vendar so bili izpadi vidnega polja pri bolnikih, ki so prejemali vigabatrin, blagi do resni.
All patients should have ophthalmological consultation before or shortly after the initiation of vigabatrin treatment. 
Pred začetkom zdravljenja z vigabatrinom ali kmalu po njem morajo vsi bolniki opraviti oftalmološki ppregled.
If you stop giving Kigabeq to your child 
Če otroku prenehate dajati zdravilo Kigabeq
Group III 
PRILOGA III
The adverse reactions listed below have been reported during pre- or post-approval use of vigabatrin worldwide. 
Med uporabo vigabatrina pred odobritvijo in po njej so po vsem svetu poročali o spodaj naštetih neželenih učinkih.
movement disorders, including dystonia, dyskinesia and hypertonia, either alone or in association with abnormalities in MRI 
vključno z distonijo, diskinezijo in hipertonijo, samostojno ali v povezavi z nepravilnostmi pri slikanju z magnetno resonanco
Abrupt withdrawal may lead to rebound seizures. 
Nenadno prenehanje zdravljenja lahko povzroči ponovne („rebound‟) napade.
100 mg tablet size: 9.4 mm x 5.3 mm 500 mg tablet size: 16.0 mm x 9.0 mm 
100 mg, velikost tablete: 9,4 mm x 5,3 mm 500 mg, velikost tablete: 16,0 mm x 9,0 mm
In resistant partial epilepsy (focal onset seizures), the recommended starting dose is 40 milligrams per kilogram daily. 
Pri rezistentni delni epilepsiji (napadih žariščnega izvora) je priporočeni začetni odmerek 40 miligramov na kilogram dnevno.
The plasma concentrations of carbamazepine, phenobarbital, and sodium valproate have also been monitored during controlled clinical trials and no clinically significant interactions have been detected. 
fenobarbitala in natrijevega valproata ter niso opazili nobenega klinično pomembnega medsebojnega delovanja.
Kigabeq is for oral or gastric administration twice daily and may be taken before or after meals. 
Zdravilo Kigabeq se daje peroralno ali prek gastrične sonde dvakrat dnevno in ga je mogoče jemati pred obroki ali po njih.
Talk to your child's doctor before you give Kigabeq if your child: has or has had depression or any other psychiatric illness in the past has had any kidney problems as he/she could develop symptoms like sedation or confusion has had any eye problems. 
Preden zdravilo Kigabeq daste otroku, se posvetujte z njegovim zdravnikom, če ima vaš otrok: - depresijo ali katero koli drugo psihiatrično bolezen ali jo je imel v preteklosti;
Visual Field Defects (VFD) 
Peroralni očistek (Cl/F)
The onset is usually after months to years of vigabatrin therapy. 
Ti izpadi običajno nastopijo več mesecev ali let po zdravljenju z vigabatrinom.
In infantile spasms (West's Syndrome), the recommended starting dose is 50 milligrams per kilogram bodyweight daily. 
Pri infantilnih spazmih (Westovem sindromu) je priporočeni začetni odmerek 50 miligramov na kilogram telesne mase dnevno.
The resulting solution is whitish and cloudy. 
Raztopina, ki nastane, je belkasta in motna.
Visual field defects which can significantly affect the ability to perform hazardous activities have been frequently reported in association with vigabatrin. 
V povezavi z vigabatrinom so pogosto poročali o izpadih vidnega polja, ki lahko pomembno vplivajo na sposobnost izvajanja nevarnih dejavnosti.
These side effects usually stop when vigabatrin doses are reduced or the medicine is gradually discontinued. 
Ti neželeni učinki običajno izginejo ob zmanjšanju odmerkov vigabatrina ali ob postopni ukinitvi zdravila.
Group I 1 
PRILOGA I
Visual disorders, which can affect the ability to cycle, climb or take part in hazardous activity, have occurred in some patients taking this medicine. 
Pri nekaterih bolnikih, ki jemljejo to zdravilo, so se pojavile motnje vida, ki lahko vplivajo na sposobnost kolesarjenja, plezanja ali sodelovanja pri nevarnih dejavnostih.
These events have been reversible following dose reduction or discontinuation of vigabatrin (see section 4.8). 
Ti dogodki so bili po zmanjšanju odmerka ali prekinitvi zdravljenja z vigabatrinom reverzibilni (glejte poglavje 4.8).
Monotherapy for infantile spasms (West's Syndrome) 
zdravljenje infantilnih spazmov (Westovega sindroma) z monoterapijo;
Abnormal Magnetic Resonance Imaging (MRI) signal changes characterised by increased T2 signal and restricted diffusion in a symmetric pattern involving the thalamus, basal ganglia, brain stem, and cerebellum have been observed in some infants treated with vigabatrin for infantile spasms. 
Pri nekaterih dojenčkih, ki so bili z vigabatrinom zdravljeni zaradi infantilnih spazmov, so pri slikanju z magnetno resonanco (MRI), opazili spremembe signala, ki jih opredeljujeta povečani signal T2 in omejena difuzija v simetričnem vzorcu, ki vključuje talamus, bazalne ganglije, možgansko deblo in male možgane.
The active substance is vigabatrin. 
- Učinkovina je vigabatrin.
optic atrophy 
optična atrofija
Visual field loss (loss of sight from the edges of your child's field of vision) may occur during treatment with vigabatrin. 
Med zdravljenjem z vigabatrinom lahko pride do izpada vidnega polja (izgube vida na robovih otrokovega vidnega polja).
Pooled data from prevalence surveys suggest that as many as 1/3 of patients receiving vigabatrin therapy have VFDs. 
Zbrani podatki iz raziskav o prevalenci kažejo, da ima izpade vidnega polja kar 1/3 bolnikov,
This medicinal product is not intended for use in women of child-bearing potential. 
To zdravilo ni namenjeno uporabi pri ženskah v rodni dobi.
Hepatobiliar y disorders hepatitis 
Bolezni jeter, žolčnika in žolčevodov hepatitis
Available data suggests that visual field defects are irreversible even after discontinuation of vigabatrin. 
Razpoložljivi podatki kažejo, da so izpadi vidnega polja celo po prekinitvi zdravljenja z vigabatrinom ireverzibilni.
General disorders and fatigue oedema, irritability administratio n site conditions 
Splošne težave in spremembe na mestu aplikacije utrujenost edem, razdražljivost
Kigabeq 100 mg is supplied in packs of 100 soluble tablets. 
Zdravilo Kigabeq 100 mg je dobavljeno v paketih s po 100 tabletami za peroralno raztopino.
Movement disorders either alone or in association with abnormalities in MRI have been reported in patients treated with vigabatrin for infantile spasms but their frequency is not known. 
Pri bolnikih, zdravljenih z vigabatrinom zaradi infantilnih spazmov, so samostojno ali v povezavi z nepravilnostmi pri slikanju z magnetno resonanco opazili motnje gibanja, vendar njihova pogostnost ni znana.
However, in rabbits, a slight increase in the incidence of cleft palate at doses of 150-200 mg/kg was seen. 
Vendar so pri kuncih, ki so prejemali odmerke 150-200 mg/kg, opazili rahlo povečanje pojavnosti razcepljenega neba.
Kigabeq 500 mg is supplied in packs of 50 soluble tablets 
Zdravilo Kigabeq 500 mg je dobavljeno v paketih s po 50 tabletami za peroralno raztopino.
Kigabeq is to be given by mouth and may be taken before or after meals. 
Zdravilo Kigabeq se daje peroralno in ga je mogoče jemati pred obroki ali po njih.
Half a tablet (500 mg) or two and a half tablets (100 mg) 
pol tablete (500 mg) ali dve tableti in pol (100 mg)
In the brain, microvacuolation due to intramyelinic oedema has been observed in white matter tracts of rat, mouse and dog at doses of 30-50 mg/kg/day. 
Pri odmerkih 30-50 mg/kg/dan so v traktu bele snovi podgan, miši in psov opazili mikrovakuolacijo zaradi intramielinskega edema.
Psychiatric events (e.g., agitation, depression, abnormal thinking, paranoid reactions) have been reported during vigabatrin treatment. 
Med zdravljenjem z vigabatrinom so poročali o psihiatričnih dogodkih (npr. vznemirjenju, depresiji, neobičajnem razmišljanju, paranoidnih reakcijah).
encephalo pathy optic neuritis brain MRI abnormalities. 
encefalop atija optični nevritis nepravilnosti možganov pri slikanju z magnetno resonanco, motnje gibanja,
What Kigabeq looks like and contents of the pack Kigabeq are white oval scored soluble tablets. 
Zdravilo Kigabeq je v obliki belih ovalnih tablet z zarezo za peroralno raztopino.
Such changes have not been seen in vigabatrin treated patients without a VFD. 
Takšnih sprememb pri bolnikih, ki so bili zdravljeni z vigabatrinom in niso imeli izpadov vidnega polja, ni mogoče opaziti.
One tablet (500 mg) and two tablets (100 mg) 
ena tableta (500 mg) in dve tableti (100 mg)
Psychiatric disorders agitation, aggression, nervousness, depression, paranoid reaction hypomania, mania, psychotic disorder suicide attempt hallucination 
depresija, paranoidna reakcija hipomanija, manija,
After administration of a single 37-50 mg/kg dose of an oral solution vigabatrin tmax was approximately 2.5 hours in neonates and infants, and 1 hour in children. 
Po dajanju enojnega odmerka peroralne raztopine vigabatrina 37-50 mg/kg je tmax znašal približno
Fill a drinking glass with one or two teaspoons of water (approximately 5 or 10 ml), according to the age of the child. Add the prescribed number of Kigabeq tablets or tablet halves to the water. 
Napolnite kozarec z eno ali dvema čajnima žličkama vode (približno 5 ali 10 ml) glede na starost otroka.
Gastrointesti nal disorders nausea, vomiting, abdominal pain 
Bolezni prebavil navzea, bruhanje,
Vigabatrin should be used with caution in patients with a history of psychosis, depression or behavioural problems. 
Pri bolnikih z anamnezo psihoze, depresije ali vedenjskih težav je treba vigabatrin uporabljati previdno.
Each soluble tablet contains 500 mg vigabatrin. 
Ena tableta za peroralno raztopino vsebuje 500 mg vigabatrina.
Kigabeq 100 mg soluble tablets Kigabeq 500 mg soluble tablets 
Kigabeq 100 mg tablete za peroralno raztopino Kigabeq 500 mg tablete za peroralno raztopino
Number of tablets (strength) Evening 
Število tablet (jakost)
Contact the doctor if your child has these psychological effects nausea (feeling sick), vomiting and abdominal pain blurred vision, double vision and uncontrolled movement of the eye, which may cause dizziness speech disorder decrease in the number of red blood cells (anaemia) 
Če so se pri vašem otroku pojavili ti psihološki učinki, se posvetujte z otrokovim zdravnikom; navzea (občutek slabosti), bruhanje in bolečine v trebuhu; zamegljen vid, dvojni vid in nenadzorovano gibanje oči, ki lahko povzroča omotičnost;
Always give this medicine to your child exactly as the doctor has told you. 
Pri dajanju tega zdravila svojemu otroku natančno upoštevajte navodila zdravnika.
If your child gets any side effects, talk to your child's doctor or pharmacist. 
Če pri otroku opazite kateri koli neželeni učinek, se posvetujte z njegovim zdravnikom ali farmacevtom.
What you need to know before your child takes Kigabeq 
Kaj morate vedeti, preden bo vaš otrok vzel zdravilo Kigabeq Ne dajajte zdravila Kigabeq:
A meta-analysis of randomised placebo-controlled trials of antiepileptic medicinal products has also shown a small increased risk of suicidal ideation and behaviour. 
Majhno povečano tveganja za samomorilne misli in vedenje je bilo dokazano tudi z metaanalizo randomiziranih, s placebom nadzorovanih preskušanj zdravil proti epilepsiji.
Vigabatrin overdose has been reported. 
Poročali so o prevelikem odmerjanju vigabatrina.